Harbin Medisan Pharmaceutical Co Ltd
Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale chemical pharmaceutical preparations in China. The company offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, and body fluid balance infusion; and other products, including oxaliplatin for injection, calcium foli… Read more
Harbin Medisan Pharmaceutical Co Ltd (002900) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.008x
Based on the latest financial reports, Harbin Medisan Pharmaceutical Co Ltd (002900) has a cash flow conversion efficiency ratio of -0.008x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-15.53 Million) by net assets (CN¥1.90 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Harbin Medisan Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Harbin Medisan Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Harbin Medisan Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Harbin Medisan Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Soft-World International
TWO:5478
|
-0.010x |
|
Zhejiang Tianzhen Technology Co. Ltd. A
SHE:301356
|
N/A |
|
Deceuninck
BR:DECB
|
0.014x |
|
STRAITS TRADG SD 1
F:W2F
|
N/A |
|
FSP Technology Inc
TW:3015
|
0.012x |
|
Goodluck India Limited
NSE:GOODLUCK
|
0.040x |
|
Maiquer Group Co Ltd
SHE:002719
|
-0.040x |
|
Hanwha Galleria Corp.
KO:452260
|
N/A |
Annual Cash Flow Conversion Efficiency for Harbin Medisan Pharmaceutical Co Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Harbin Medisan Pharmaceutical Co Ltd from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.16 Billion | CN¥30.69 Million | 0.014x | -14.66% |
| 2023-12-31 | CN¥2.15 Billion | CN¥35.69 Million | 0.017x | -76.43% |
| 2022-12-31 | CN¥2.05 Billion | CN¥144.64 Million | 0.070x | +1290.28% |
| 2021-12-31 | CN¥2.12 Billion | CN¥-12.53 Million | -0.006x | -135.40% |
| 2020-12-31 | CN¥1.79 Billion | CN¥-4.51 Million | -0.003x | -101.46% |
| 2019-12-31 | CN¥1.85 Billion | CN¥320.14 Million | 0.173x | +16.45% |
| 2018-12-31 | CN¥1.97 Billion | CN¥292.46 Million | 0.148x | +21.92% |
| 2017-12-31 | CN¥1.83 Billion | CN¥223.46 Million | 0.122x | -57.43% |
| 2016-12-31 | CN¥808.17 Million | CN¥231.18 Million | 0.286x | +3.68% |
| 2015-12-31 | CN¥727.97 Million | CN¥200.85 Million | 0.276x | +44.50% |
| 2014-12-31 | CN¥609.16 Million | CN¥116.31 Million | 0.191x | -58.28% |
| 2013-12-31 | CN¥365.13 Million | CN¥167.10 Million | 0.458x | +27.29% |
| 2012-12-31 | CN¥342.72 Million | CN¥123.22 Million | 0.360x | -- |